hyperthermia and rhabdomyolysis/ccm board review

8/10/2019 Hyperthermia and rhabdomyolysis/CCM board review

http://slidepdf.com/reader/full/hyperthermia-and-rhabdomyolysisccm-board-review 1/49

!"#$%&'()*+,!"#'(%&'()*+ +./

0&+1/$)"$2"*3

4+.*5' 67 8*))'()+., 97:7;'*22 <$(.'22 9'/*5+2 <$22'='>&' 9'%&$/*3% !$3#*%+2

!$?3%$., >'@+3



F1G'5EB'3•

F?%2*.' ('H+()*.= %'5&.*I?'3 D$()+.+=')'.% $D &"#$%&'()*+• :'35(*1' #('/*3#$3*.= D+5%$(3, 52*.*5+2

)+.*D'3%+E$.3 +./ )+.+=')'.% $D &'+%3%($J'

• :*35?33 )+.+=')'.% $D )+2*=.+.% &"#'(K%&'()*+ +./ .'?($2'#E5 )+2*=.+.% 3"./($)'

• :'35(*1' 'E$2$=*'3 +./ )+.+=')'.% $D(&+1/$)"$2"3*3



>')#'(+%?(' 0'=?2+E$.

Temperature-sensitive receptors

Skin Viscera Great vessels

Anterior hypothalamus

LH'+E.=M+3$/*2+E$.

9?352' %$.'

L&*B'(*.=M+3$5$.3%(*5E$.

9?352' %$.'

H e a

t

C o

l d



N#*/')*$2$=" $D !"#$%&'()*+• OB'(+=' $D PQR /'+%&3S"( *. T7L7

– UVW $D /'+%&3 XPU "'+(3 $2/ –

9'. XH$)'.• OY'5%'/ *./*B*/?+23

– T(1+. /'3E%?%' – ;*2/'(.'33S3#$(%3 '.%&?3*+3%3

• F55?(3 "'+( ($?./, +." 52*)+%'



!"#$%&'()*+•

<$(' %')#'(+%?(' Z[U\< ]RU\^_• <2+33*`5+E$.

– 9*2/ [aK[U\< ]RVKRU\^_ – 9$/'(+%' aQK[a\< ]QaKRV\^_ – L'B'(' ZaQ\< ]ZQa\^_

• >(+?)+ 52+33*`5+E$. – 9$/'(+%' [aK[b\< ]RVKR[\^_ – L'B'(' Z[a\< ]ZRV\^_



c('/*3#$3*.= ^+5%$(3•

A.5('+3'/ &'+% 2$33 – N.B*($.)'.%+2 '@#$3?(' – A./?5'/ B+3$/*2+E$. ]/(?=3_

• :'5('+3'/ &'+% #($/?5E$. – N./$5(*.' /*3$(/'(3 – A.3?d5*'.% D?'2 ]&"#$=2"5')*+_

• A)#+*('/ %&'()$('=?2+E$. – <'.%(+2 +./ #'(*#&'(+2 /"3D?.5E$.



e7 ;&*5& $.' $D %&' D$22$H*.= *3 2*J'2" %$ 1'#('3'.% *. + #+E'.% H*%& 3'B'('&"#$%&'()*+ ]5$(' %')#'(+%?(' ZaQ\<_f

O7 !"#'(=2"5')*+

g7 M$2?)' $B'(2$+/<7 6$H &')+%$5(*%:7 L&*B'(*.=

N7 A.5('+3'/ E/+2 B$2?)'



9+.*D'3%+E$.3 $D !"#$%&'()*+• g(+/"5+(/*+• !"#$%'.3*$.•

L"3%')*5 B+35?2+( ('3*3%+.5'• <$./?5E$. +1.$()+2*E'3

– O%(*+2 `1(*22+E$. – M'.%(*5?2+( +((&"%&)*+3 – O3"3%$2'



N<h *. !"#$%&'()*+



9+.*D'3%+E$.3 $D !"#$%&'()*+• L&*B'(*.= +13'.% *D Z[VK[a\<• 0'3#*(+%$(" (+%' +./ E/+2 B$2?)' •

:*?('3*3• <$.D?3*$., 2'%&+(="• A2'?3• !'#+E5 /"3D?.5E$.• g2''/*.=



6+1$(+%$(" ^*./*.=3• !')+%$5(*%• c2+%'2'%3• i$()+2 c>Sc>> *.*E+22"• gTi, 5('+E.*.'• M+(*+12' '2'5%($2"%'3

• !"#'(=2"5')*+• O5*/')*+• i$ .''/ %$ 5$(('5%

Ogh D$( %')#'(+%?('



9+.+=')'.% $D !"#$%&'()*+• O*(H+"

– F($%(+5&'+2 ($?%' #('D'(('/ –

9$.*%$( N>> 5?Y #('33?('• L?##2')'.%+2 F a • <c0

– c?23'2'33 ]5&'5J D$( [VKbU 3'5_ – i$.#'(D?3*.= (&"%&)



O((&"%&)*+3 *. !"#$%&'()*+• g(+/"5+(/*+, +%(*+2 +((&"%&)*+3

– 0'H+()*.=• M'.%(*5?2+( `1(*22+E$.

– :'`1(*22+E$. – 0'H+()*.= –

OB$*/ /(?=3 *D Z[V\ <• O3"3%$2', cNO – OB$*/ /(?=3 *D Z[V\ <



9+.+=')'.% $D !"#$%&'()*+• 0'H+()*.=• >')#'(+%?(' )$.*%$(*.=•

AM C?*/3 ]+B$*/ 0*.='(j3 2+5%+%'_• h+3%(*5 /'5$)#('33*$.• T(*.+(" 5+%&'%'(• 6+1$(+%$(" 3%?/*'3 ].$ `.='(3E5J3_• >('+% +33$5*+%'/ 5$./*E$.3



2. Which one of the following techniques

is the best intervention for a patient withcore temperature 30º C (86 F) with pulse50/min and BP 80/56 mm Hg?

A. Forced air warming blanketB. Gastric lavage with heated salineC. Peritoneal lavageD. Cardiopulmonary bypassE. ECMO



c+33*B' N@%'(.+2 0'H+()*.=• 6'+3% *.B+3*B'• ;+() '.B*($.)'.%•

A.3?2+E$.• c+E'.% )?3% ='.'(+%' &'+%• L$2' )'%&$/ $.2" *. )*2/

&"#$%&'()*+• 0'H+()*.= (+%' V7UKa <S&

HHH7('B'('3?(B*B+275$)



O5EB' N@%'(.+2 0'H+()*.=• N@%'(.+2 +##2*5+E$. $D &'+%

– g2+.J'%3, 2+)#3 – A))'(3*$. – ̂ $(5'/ +*( – 0'3*3EB' #$2")'( 12+.J'%3

•

OB+*2+12', .$.*.B+3*B'• 0'H+()*.= (+%' e7UKa7U <S&



O5EB' <$(' 0'H+()*.=• !'+%'/, &?)*/*`'/ F a ]bVKbU# <_• !'+%'/ AM C?*/3 ]bVKba # <, 3&$(%

%?1*.=_• h+3%(*5, 12+//'(, ('5%+2 2+B+='• c'(*%$.'+2 2+B+='• c2'?(+2 2+B+='• N./$B+35?2+( H+()*.=



O5EB' <$(' 0'H+()*.=• N@%(+5$(#$('+2 %'5&.*I?'3

– !')$/*+2"3*3 – <$.E.?$?3 /*+2"3*3 %'5&.*I?'3 – <+(/*$#?2)$.+(" 1"#+33 – N<9F



F?%5$)' D($) !"#$%&'()*+• i$ ('2*+12' #('/*5%$(3 $D /'+%&• c$$( #($=.$3*3

– k l XeV ))$2S6 – L&$5J, B+3$+5EB' /(?= ?3'

• <$.E.?' 'Y$(%3 ?.E2 [a\< ]RV\^_

• A./*B*/?+2*m' %'()*.+E$. $D 'Y$(%3



c'(*$#'(+EB' !"#$%&'()*+•

>')#'(+%?(' Z[U $( [P\<• c'(*$#'(+EB' 5$)#2*5+E$.3

– 9$(%+2*%" – A.D'5E$.3 – g2''/*.=

• A.%(+$#'(+EB'SA<T )'+3?('3 – 0'H+()*.= /'B*5'3 – ;+() AM C?*/3 ]be\<_



!"#'(%&'()*+



!"#'(%&'()*+ L"./($)'3• !'+% 3%($J'

– aVV[n eb,QVV /'+%&3 *. ZeV/+"3 *. ^(+.5'

• 9+2*=.+.% &"#'(%&'()*+•

i'?($2'#E5 )+2*=.+.%3"./($)'



!'+% L%($J' L"./($)'3• <2+33*5 &'+% 3%($J'

– N2/'(2" H*%& 5&($.*5 *22.'33 –

:'B'2$#3 $B'( /+"3 – L*=.*`5+.% /'&"/(+E$.

• N@'(E$.+2 &'+% 3%($J' – O%&2'%'3, )*2*%+(" ('5(?*%3 – 9*2/ /'&"/(+E$.



c('/*3#$3*.= ^+5%$(3• A.5('+3'/ &'+% #($/?5E$.

– N@'(5*3' – :(?=3 ]3")#+%&$)*)'E5 +='.%3_ – N.B*($.)'.%+2 &'+%

• :'5('+3'/ &'+% 2$33 – N.B*($.)'.%+2 &'+%, &?)*/*%" – <+(/*$B+35?2+( /*3'+3' – :(?=3 ]+.E5&$2*.'(=*5 +='.%3_



<2*.*5+2 9+.*D'3%+E$.3• >')#'(+%?(' ] $bV\<, eVb\^_• <iL /"3D?.5E$.

–

<'('1'22+( /"3D?.5E$. – L'*m?('3, 5$)+

• >+5&"5+(/*+• !"#$%'.3*$.• >+5&"#.'+



6+1$(+%$(" 9+.*D'3%+E$.3• 0'3#*(+%$("

+2J+2$3*3•

9'%+1$2*5 +5*/$3*3 – 6+5%+%'

• 0&+1/$)"$2"3*3

• 0'.+2 *.3?d5*'.5"• <$+=?2$#+%&"• !'#+E5 /"3D?.5E$.• M+(*+12' '2'5%($2"%'3



^'+%?('3 $D !'+% L%($J'

^'+%?(' <2+33*5 N@'(E$.+2!"#$%'.3*$. aVK[VW i$% J.$H.

0&+1/$)"$2"3*3 9*2/S)$/'(+%' L'B'('

0'.+2 D+*2?(' T.5$))$. <$))$.

6+5E5 +5*/ 9*2/S)$/'(+%' L'B'('

h2?5$3' A.5('+3'/ 6$H

:A< 9*2/S)$/'(+%' L'B'('

!!"#$%&'(' *+ ,- './ 012- 0'1, 344567789:;



<$$2*.= 9'%&$/3• <$./?5EB' 5$$2*.=

– A))'(3*$. *. 5$2/ H+%'( – A5' #+5J3 – LJ*. )+33+=' %$ 5$?.%'(+5%

B+3$5$.3%(*5E$.• NB+#$(+EB'S5$.B'5EB' 5$$2*.=

– ;+() H+%'( )*3% ]eUKaV\<_ – O*( C$H D($) D+.3



F%&'( 9'%&$/3 $D <$$2*.=• c'(*%$.'+2 $( =+3%(*5 2+B+='• <+(/*$#?2)$.+(" 1"#+33• L?(D+5' 5$$2*.= /'B*5'3• N./$B+35?2+( 5$$2*.=•

<$2/ AM C?*/3 ]b

<_



9+.+=')'.% $D !'+% L%($J'• <$$2 ?.E2 [QK[Q7Q\< ]eVV7bKeVa\^_• O*(H+" #($%'5E$.• L?##2')'.%+2 F a • A.%(+B'.$?3 C?*/3• T(*.+(" 5+%&'%'(• 9$.*%$( H*%& %&'()*3%$(



F?%5$)' $D !'+% L%($J'• <$(('2+%'3 H*%& /?(+E$., *.%'.3*%"• A.5('+3'/ )$(%+2*%"

– F2/'( +=' – T./'(2"*.= 5$./*E$.3 – !"#$%'.3*$. – 6+5%+%' ]52+33*5 &'+% 3%($J'_ – 0'.+2 D+*2?(' – <$)+



4. Which one of the following agents is

safe to administer to a patient requiringemergency surgery who has a familyhistory of malignant hyperthermia?

A. Succinylcholine and nitrous oxideB. Succinylcholine and halothaneC. Rocuronium and nitrous oxideD. Rocuronium and enfluraneE. Rocuronium and halothane



9+2*=.+.% !"#'(%&'()*+• <2*.*5+2 3"./($)'

– !"#'(%&'()*+ –

9?352' 5$.%(+5E$. – <+(/*$B+35?2+( *.3%+1*2*%"

• h'.'E5 /'D'5% *. <+ ll %(+.3#$(% *.3J'2'%+2 )?352'

• >(*=='(3 o &+2$%&+.', 3?55*."25&$2*.'



<2*.*5+2 9+.*D'3%+E$.3• 9?352' (*=*/*%"

– 9+33'%'( 3#+3)• >+5&"5+(/*+• A.5('+3'/ c+<F a • !"#'(%'.3*$.• LJ*. )$p2*.=



<2*.*5+2 9+.*D'3%+E$.3• A.5('+3'/ %')#'(+%?('• O5*/$3*3• O((&"%&)*+3• !"#$%'.3*$.• 0&+1/$)"$2"3*3• !"#'(J+2')*+



9+.+=')'.% $D 9!•

L%$# $Y'./*.= /(?=• L%$# 3?(='(" *D #$33*12'• :+.%($2'.' ]a7U )=SJ= IU )*., )+@ eV )=SJ=_• NB+#$(+EB' 5$$2*.=• 9+*.%+*. /*?('3*3• OB$*/ 5+25*?) 5&+..'2 12$5J'(3• L?##$(EB' 5+('

www.mhaus.org, 1-800-MH-HYPER, 1-315-464-7079 (outside U.S)



<2*.*5+2 <$?(3'• F.3'% ?3?+22" *. eK[ /+"3

– :(?= *.*E+E$. – <&+.=' *. /$3'

• :?(+E$. eK[ H''J3 – 6$.='( H*%& /'#$% D$()3

• :'+%& D($) +3#*(+E$., +((&"%&)*+3



0&+1/$)"$2"3*3• 9?352' *.G?(" l ('2'+3' $D 5'22 5$.%'.%3• >(+?)+E5 +./ .$.%(+?)+E5• !"#'(<k')*+

– 6'33 3'B'(' D$(), 5&($.*5• c+%&$='.'3*3

– :*('5% *.G?(" %$ 3+(5$2'))+ $(/'#2'E$. $D O>c

– A.5('+3' *. *.%(+5'22?2+( <+ l



<+?3'3 $D 0&+1/$)"$2"3*3• 9'%+1$2*5

+1.$()+2*E'3 – k, cF b, <+ – !"#'($3)$2+2*%"

• >$@*.3, /(?=3 – L%+E.3 – <$5+*.', &'($*. – c($#$D$2

• h'.'E5 /'D'5%3• c&"3*5+2 *.G?("• N@'(E$. ]'@'(5*3',

3'*m?('3_• >')#'(+%?(' '@%(')'3• A.D'5E$.3 ]!eie_• 9?352' &"#$@*+

• g+(*+%(*5 3?(='("



<2*.*5+2 9+.*D'3%+E$.3• 9"+2=*+3, )?352' 3H'22*.= +./ #+*.• :*35$2$('/ ?(*.'• 9?352' '.m")'3• N2'5%($2"%' +1.$()+2*E'3• 0+#*/ 5('+E.*.', 2$H ^N i+ ]ZeW_• T(*.' ]l_ D$( 12$$/ 1?% .$ ('/ 5'223 $.

)*5($35$#*5 '@+)*.+E$.



9+.+=')'.%• ^2?*/ ('#2+5')'.% ]?(*.' $?%#?% aK[ )2SJ=S&_

– i$()+2 3+2*.' – g*5+(1$.+%'K5$.%+*.*.= C?*/3

• 9+..*%$2 ?3' 5$.%($B'(3*+2• 9$.*%$( '2'5%($2"%'3• >('+% &"#$5+25')*+ #<.= *D 3")#%$)+E5• 0'.+2 ('#2+5')'.% %&'(+#"• 9$.*%$( D$( 5$)#+(%)'.% 3"./($)'3

- Bosch X, et al. NEJM 2009;361:62



L?))+("• 0'5$=.*m' +./ +55$?.% D$( #&"3*$2$=*5+2 5&+.='3

*. &"#$K +./ &"#'(%&'()*+• <&$$3' ('H+()*.= %'5&.*I?'3 1+3'/ $. 52*.*5+2

5&+(+5%'(*3E53 +./ +B+*2+12' ('3$?(5'3• <$./?5EB' $( 'B+#$(+EB' 5$$2*.= *3 %&' #(*)+("

*.%'(B'.E$. *. &'+% 3%($J'• :+.%($2'.' *3 ?3'/ %$ /'5('+3' &'+% #($/?5E$. *.

)+2*=.+.% &"#'(%&'()*+ +./ i9L• A.5('+3*.= ?(*.' $?%#?% H*%& AM C?*/3 *3 %&'

)+*.3%+" $D %('+E.= (&+1/$)"$2"3*3



>&+.J "$? D$( "$?(+p'.E$.

hyperthermia and rhabdomyolysis/ccm board review

Documents